Cordes M, Hierholzer J, Schelosky L, Schrag A, Richter W S, Eichstädt H, Schulze P E, Poewe W, Felix R
Neurology Clinic, Rudolf Virchow University Clinic, Free University, Berlin, Germany.
J Nucl Med. 1996 Jan;37(1):22-5.
Recently, [123I]iodo-lisuride was synthesized for possible applications in SPECT studies. The purpose of this investigation was to compare the striatal binding and kinetics of this radioligand in patients with Parkinson's disease and normal controls.
Six patients with Parkinson's disease and three normal controls were examined. After intravenous injection of 111 MBq [123I]iodo-lisuride, sequential SPECT examinations at 20, 40, 80 and 120 min were performed. For each SPECT series the basal ganglia-to-cerebellum ratio of tracer accumulation was calculated. In one patient a repeat SPECT examination was undertaken under identical conditions to test the reproducibility of the procedure. In two other patients a second SPECT examination was performed after injection of cold lisuride as a receptor saturation study. In addition, the time course of the radioactivity was measured in the plasma and red blood cells in each individual.
In both patients and controls, the highest tracer accumulation was found within the striatum. The basal ganglia-to-cerebellum ratio was 1.182 and 1.303 at 20 min, 1.353 and 1.450 at 40 min, 1.490 and 1.533 at 80 min, 1.550 and 1.583 at 120 min for patients and controls, respectively, which was not statistically different. In the saturation study, 50 micrograms and 100 micrograms cold lisuride led to a 28% and 33% reduction, respectively, of the basal ganglia-to-cerebellum ratio at 120 min. The ligand showed a rapid decline in plasma and red blood cells. The percent injected dose per liter was calculated to be 1.6 and 0.9, respectively, for plasma and red blood cells at 20 min.
Iodine-123-iodo-lisuride SPECT seems useful for imaging intact striatal dopamine D2 receptors in patients with Parkinson's disease and may provide clinically relevant information for quantitative assessment of the availability and integrity of dopamine D2 receptors.
最近，合成了[123I]碘利舒脲，用于单光子发射计算机断层扫描（SPECT）研究的可能应用。本研究的目的是比较这种放射性配体在帕金森病患者和正常对照者纹状体中的结合及动力学情况。
检查了6例帕金森病患者和3例正常对照者。静脉注射111 MBq [123I]碘利舒脲后，在20、40、80和120分钟进行连续SPECT检查。对于每个SPECT系列，计算示踪剂积聚的基底节与小脑比值。在1例患者中，在相同条件下进行重复SPECT检查以测试该程序的可重复性。在另外2例患者中，注射冷利舒脲后进行第二次SPECT检查作为受体饱和研究。此外，在每个个体中测量血浆和红细胞中的放射性时间进程。
在患者和对照者中，纹状体内均发现最高的示踪剂积聚。患者和对照者在20分钟时基底节与小脑比值分别为1.182和1.303，40分钟时为1.353和1.450，80分钟时为1.490和1.533，120分钟时为1.550和1.583，差异无统计学意义。在饱和研究中，50微克和100微克冷利舒脲分别导致120分钟时基底节与小脑比值降低28%和33%。该配体在血浆和红细胞中迅速下降。20分钟时血浆和红细胞中每升注射剂量的百分比分别计算为1.6和0.9。
碘-123-碘利舒脲SPECT似乎有助于帕金森病患者完整纹状体多巴胺D2受体的成像，并可能为多巴胺D2受体的可用性和完整性的定量评估提供临床相关信息。
